BlackRock Inc. acquired 3,116,487 shares of Opus Genetics for approximately $12.81 million. This investment establishes a 3.77% ownership stake in the company. Institutional investors now control 14.97% of the firm's total shares.
Opus Genetics recently reported a quarterly loss of $0.14 per share. This result outperformed analyst expectations of a $0.16 loss per share. However, the company missed its quarterly revenue expectations significantly.
Market analysts maintain a Moderate Buy consensus rating on the stock. The current average price target for Opus Genetics is $10.69.